INTRODUCTION AND OBJECTIVES: Sex cord-gonadal stromal tumors (SCGS) of the testicle, primarily made up of Leydig cell and Sertoli cell tumors, are rare testicular neoplasms. Single institutional studies suggest that metastases are rare and survival excellent. We utilized the SEER database to characterize risks of metastasis in patients with SCGS tumors.
METHODS: We interrogated the SEER database from 1973 to 2010 to identify all Leydig cell (code -86503) and Sertoli cell (code -86403) tumors among male patients. Data collected and analyzed included patient age and race; SEER stage including limited to primary site (Localized), the presence of disease in retroperitoneal lymph nodes (Regional) and distant metastases (Distant); as well as cancer-specific and overall survival. RESULTS: We identified 53 patients with Leydig cell tumors and 23 with Sertoli cell tumors. Sertoli cell tumors were fairly evenly distributed overall all age groups while Leydig cell tumors were concentrated among ages 30-59. Using SEER extent of disease, 79% were found to be Localized and 21% Distant on initial presentation with equal distribution among patients with Leydig and Sertoli cell tumors. Median survival of patients presenting with metastases was 27 months. Patients with apparently Localized disease had a 13% chance of developing metastases at a median of 17 months. Patients with SCGS tumors of the testicle whether localized or metastatic had a significantly poorer survival compared to patients with germ cell tumors.
CONCLUSIONS: This study represents the largest analysis of outcomes for patients with SCGS tumors. These neoplasms have a high risk of presenting with metastasis (20%) than previously recognized as as well as a significant risk (13%) of patients with Localized tumor developing a recurrence. Patients with metastatic SCGS tumors are at higher risk of dying from their disease than patients with metastatic germ cell neoplasms likely due to inherent resistance to radiation and chemotherapy. RESULTS: FSEs were performed on 142 testicular lesions during inguinal exploration of the affected testis. Germ cell tumors (GCT) and non-GCT pathologies were correctly identified in 106 cases (74.6%, 46 non-seminomas, 60 seminomas) and 35 cases (24.6%), respectively. One case was incorrectly classified as non-malignant hypocellular nodule on FSE. However, final pathology revealed a seminoma. The patient underwent a secondary inguinal orchiectomy and remains disease-free 6 years post orchiectomy under active surveillance. No patient underwent unnecessary orchiectomy due to an incorrectly classified testicular GCT. According to our data, FSE has a sensitivity of 99% (95% CI 95%-100%), a specificity of 100% (95% CI 85%-100%), a positive predictive value of 100% (95% CI 95%-100%) and a negative predictive value of 97% (95% CI 85%-100%).
CONCLUSIONS: FSE is a useful diagnostic tool, which reliably predicts the presence or absence of GCT and thus is helpful to guide intraoperative management of testicular lesions particularly in patients with inconclusive preoperative results (i.e. negative tumor markers). To minimize the rate of unnecessary orchiectomies, these patients should only be treated in institutions where FSE is available. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1083 post-chemotherapy setting for metastatic seminoma. However, false positive results can be a problem. We sought to identify a new methodology to interpret FDG-PET scans using a more objective approach to reduce false positive results. METHODS: We identified patients who had FDG-PET imaging available for re-review with a diagnosis of germ cell tumor at our institution from 2006 to 2016. Twenty-six scans were identified. All images were re-reviewed by an experienced radiologist who was blinded to patient treatments and outcomes. Radiographic variables recorded were mass size, standard uptake values (SUV), liver and blood pool values, and date of scan. Liver and blood ratios were calculated for each scan by dividing the SUV of the index lesion by the liver and blood pool values, respectively. A ratio of 1 would be considered a negative scan. A 5-point scale was assigned to each scan based on the dominant FDG-avid lesion using a similar system to the Deauville scale for lymphoma with 5 representing significant uptake and 1 for no uptake.
RESULTS: A total of 26 patients were identified. The median follow-up from the PET scan was 21 months (range 1-96). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the original PET scan interpretation was 100%, 81%, 77%, and 100% respectively. If the liver ratio was included as an objective measurement, the sensitivity, specificity, PPV, and NPV would have improved to 100%, 88%, 83%, 100%, respectively. Thus, the increase in specificity would have resulted in a decrease of false positive results. Of the 26 PET studies, 3 (12%) were false positives and 0 (0%) were false negatives. Four patients underwent a RPLND due to positive findings on the PET study. Of these, 3 were found to have seminoma and 1 had necrosis on final pathology. The median SUV value of the 3 PCRPLND patients with seminoma was 6.7, with a liver ratio of 2.68. The patient with necrosis had an SUV of 2.5, with liver ratio of 0.9. The blood ratio and 5-point scoring system did not add additional significant information.
CONCLUSIONS: By including the liver ratio in interpreting PET scans, we believe we can reduce the number of false positive scans.
Source of Funding: none

MP80-10 MIDLINE EXTRAPERITONEAL APPROACH TO RETROPERITONEAL LYMPH NODE DISSECTION IN TESTICULAR CANCER: MINIMIZING SURGICAL MORBIDITY
Sumeet Syan-Bhanvadia*, Soroush Bazargani, Thomas Clifford, Jie Cai, Gus Miranda, Hooman Djaladat, Anne Schuckman, Siamak Daneshmand, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Retroperitoneal lymph node dissection (RPLND) is an important component of the management of testicular germ cell tumor (GCT) but carries significant morbidity. Herein we describe our updated experience with a midline extraperitoneal (EP) approach to RPLND for seminomatous and nonseminomatous GCT that minimizes perioperative morbidity.
METHODS: 122 consecutive patients from an IRB approved database underwent RPLND from 2010-2015. Patients requiring aortic resection, retrocrural dissection or access to intraperitoneal disease were excluded. The remaining 69 patients underwent midline EP-RPLND. All post-chemotherapy (PC) cases underwent bilateral template dissection; all primary cases underwent extended ipsilateral templates. Perioperative and long-term outcomes were analyzed and a descriptive analysis using SAS was performed.
RESULTS: 68 patients underwent midline EP-RPLND successfully (98.6%). Median age was 28 years. On pre-operative imaging the size of retroperitoneal mass or lymphadenopathy was <2 cm in 29 patients, 2-5 cm in 15 patients, and >5 cm in 24 patients, of which 19 were >10cm. 3 patients underwent cavectomy. Median EBL was 325 mL ). Median number of lymph nodes (LN) resected was 36 (IQR: 24.5-49); median number of positive nodes was 1 (IQR: 0-4). Median return of bowel function was 2 days (IQR: 1-2) and LOS was 3 days (IQR: 3-4). There were no cases of ileus. 11 patients (16.2%) had 30-day complications: 6 (55%) were Clavien grade 1, 5 (45%) were grade 2. There was 1 long-term complication (1.5%), which was grade 3b. Antegrade ejaculation rates were 91.6% in the primary group and 96.8% in the PC group.
CONCLUSIONS: Midline EP-RPLND can be performed safely without compromising completeness of resection. This approach is associated with a faster return of bowel function, lower rates of ileus and shorter LOS.
Source of Funding: none
MP80-11 PENILE SPARING SURGERY FOR PENILE CANCER: A MULTICENTER INTERNATIONAL RETROSPECTIVE COHORT
INTRODUCTION AND OBJECTIVES: Penile cancer (PC) is a rare and potentially disfiguring disease. There have been great strides made to improve cancer control, as well as to decrease treatmentassociated morbidities. We present our outcomes using penile sparing surgery (PSS) for the treatment of PC in the largest cohort known to date.
METHODS: 1439 patients were retrospectively identified to have undergone PSS for PC from July 2000 to June 2015 at five international institutions of excellence. PSS consisted of laser ablation, wide local excision, circumcision, and partial/total glansectomy. Patient demographics and clinical characteristics were summarized using descriptive statistics. Univariate analyses were performed using the chisquare test for categorical variables. Kaplan Meier survival curves were applied to determine overall recurrence free survival (RFS) as well RFS stratified by pathologic stage and surgical intervention.
RESULTS: Median patient age of our cohort was 63 years old. Median patient follow up was 40 months. 23.9% of all patients recurred after PSS. 5 year RFS by pT stage was Ta/Tis: 58.0%, T1: 55.5%, and T2: 49.8%. RFS for all patients undergoing PSS was 55.6%( 1 year: 77.3%, 2 year: 67.3%, 5 year: 55.6%). Treatment modality (p¼0.056) and pT stage (p¼0.99) did not significantly correlate with RFS at 5 years. Patients with higher pT tumors underwent more aggressive interventions (p <0.001).
CONCLUSIONS: PSS is indicated for appropriately selected patients with PC. Treatment modality and pT stage were not significant predictors of RFS. Close follow-up remains a critical component of all treatment considerations.
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